Promising results were obtained by Gucalp et al. [44] in a Phase II trial that showed clinical benefit rate of 19% for 6 months in 424 patients with ER/PgR-negative BC underwent bicalutamide 150 mg daily with minimal toxicity. The gene discussed is PGR; the disease is breast cancer.